Vyant Bio is a biotechnology company reinventing drug discovery for neurodevelopmental and neurodegenerative disorders. Co.'s central nervous system (CNS) drug discovery platform combines human-derived organoid models of brain disease, scaled biology, and machine learning. Co.'s platform is designed to: elucidate disease pathophysiology; formulate therapeutic hypotheses; identify and validate drug targets, cellular assays, and biomarkers; and guide clinical trial patient selection and trial design. Co.'s programs are focused on identifying small molecule clinical candidates for rare CNS genetic disorders including Rett Syndrome, CDKL5 Deficiency Disorders and Parkinson's Disease. We show 9 historical shares outstanding datapoints in our VYNT shares outstanding history coverage, used to compute VYNT market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing VYNT market cap history over the course of time is important for investors
interested in comparing VYNT's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of VYNT versus a peer is one thing; comparing
VYNT market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like VYNT can fluctuate over the course of history.
With this page we aim to empower investors researching VYNT by allowing them to research the VYNT market cap history. |
Free VYNT Email Alerts:
Video: The Importance of Market Cap
